国药股份代董事长请辞，内部老将暂代职务

Core Viewpoint - The recent leadership changes at China National Pharmaceutical Group Corporation (Sinopharm) indicate a potential shift in management strategy, as multiple key executives, including the chairman and general manager, have resigned due to retirement and work changes, with no new chairman announced yet [1][4][5]. Company Summary - Sinopharm announced the resignation of three key executives, including the chairman and general manager, due to retirement and work changes [1]. - Liu Yuetao, the current party secretary, will act as the general manager, and he, along with Zhou Bin, has been nominated as candidates for the eighth board of directors [1][5]. - The company has not yet disclosed a new chairman following the retirement of the previous chairman, Jiang Xiuchang, in November 2024 [4][5]. Industry Summary - Sinopharm operates primarily in pharmaceutical distribution, covering various business segments including drug distribution, retail, and logistics, with a strong presence in Beijing [6]. - The company is a leading player in the narcotic drug wholesale market, holding over 70% market share in the special narcotic drug distribution sector as of 2022 [9]. - The pharmaceutical distribution industry has faced challenges, with a significant slowdown in growth, as evidenced by a mere 0.6% year-on-year growth in 2024, marking the lowest growth rate in 15 years [11].